VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 303.00K | 258.00K | 244.00K | -15.00K | 234.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 303.00K | 258.00K | 244.00K | -15.00K | 234.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 303.00K | 258.00K | 244.00K | -15.00K | 234.00K |
| SG&A Expenses | 5.63M | 4.40M | 4.37M | 4.27M | 4.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.85M | 20.31M | 16.05M | 14.48M | 15.35M |
| Operating Income | -19.55M | -20.05M | -15.80M | -14.50M | -15.12M |
| Income Before Tax | -18.90M | -19.42M | -15.10M | -13.64M | -14.09M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -- |
| Earnings from Continuing Operations | -18.90M | -19.42M | -15.10M | -13.64M | -14.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.90M | -19.42M | -15.10M | -13.64M | -14.09M |
| EBIT | -19.55M | -20.05M | -15.80M | -14.50M | -15.12M |
| EBITDA | -19.49M | -20.00M | -15.76M | -14.46M | -15.08M |
| EPS Basic | -0.45 | -0.54 | -0.47 | -0.43 | -0.46 |
| Normalized Basic EPS | -0.28 | -0.34 | -0.30 | -0.27 | -0.29 |
| EPS Diluted | -0.45 | -0.54 | -0.47 | -0.43 | -0.46 |
| Normalized Diluted EPS | -0.28 | -0.34 | -0.30 | -0.27 | -0.29 |
| Average Basic Shares Outstanding | 42.23M | 35.75M | 31.93M | 31.56M | 30.71M |
| Average Diluted Shares Outstanding | 42.23M | 35.75M | 31.93M | 31.56M | 30.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |